AMARILLO, Texas, April 6 /PRNewswire/ -- Amarillo Biosciences Inc.
(Nasdaq: AMAR) today announced that enrollment has opened for its final Phase
3 clinical trial on the use of low dose oral interferon alpha as a treatment
for dry mouth in Sjogren's syndrome patients. Sjogren's syndrome affects
1-2 million patients in the United States and represents a significant market
for Amarillo Biosciences, Inc.
Amarillo Biosciences is working with PPD Pharmaco, a clinical research
organization, to conduct the Phase 3 clinical trials for the use of low dose
oral interferon alpha for the treatment of Sjogren's syndrome. The trial is
being conducted at 50 sites in the United States, and completion of enrollment
is expected during 1999.
Dr. Joseph M. Cummins, President and CEO of Amarillo Biosciences, stated,
"I am extremely pleased to have executed the budget agreement with PPD
Pharmaco in order to complete our Phase 3 clinical trials for the use of low
dose oral interferon alpha as a treatment for dry mouth in Sjogren's syndrome
patients. It is a pleasure to be able to work with a clinical research
organization of their caliber."
Founded in 1984, Amarillo Biosciences is a world leader in the development
of low dose oral interferon alpha as a treatment for a variety of conditions
including Sjogren's syndrome, fibromyalgia, opportunistic infections in
patients who are HIV positive, hepatitis B and hepatitis C.
Interferon plays a critical role in immune system modulation. High dosage
injectable interferon is currently used for the treatment of cancer, multiple
sclerosis and hepatitis in humans. Amarillo Biosciences is an emerging
biopharmaceutical company incorporated in 1984 and dedicated to the
development of oral and topical applications of low dose interferon for human
and animal health applications. Low dose interferon has the potential to be
less costly and to have fewer side effects than high dose injectable
interferon.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the company's other product
candidates and other risks detailed from time to time in the company's filings
with the Securities and Exchange Commission. In particular, see "Item 1. The
Description of Business" of the company's Form 10-KSB for the year ended
Dec. 31, 1997.
SOURCE Amarillo Biosciences Inc.
 back to top
Related links:
http://www.amacell.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html or fax,
800-758-5804, ext. 118055
CONTACT:
Kathleen L. Kelleher, COO and Vice President
Business Development of Amarillo Biosciences Inc., 806-376-1741,
or email, ABI@AmarBio.com
|
